DEF: Rallybio Sets Date for 2025 Annual Stockholders Meeting, Board Recommends Director Elections and Accounting Firm Ratification

Rallybio Corporation announces its 2025 Annual Meeting of Stockholders to be held virtually on May 13, 2025, with key proposals including the election of directors and ratification of the company's independent accounting firm.

Summary

• Rallybio Corporation will hold its 2025 Annual Meeting of Stockholders on May 13, 2025, in a virtual format.
• Stockholders will vote on the election of Martin W. Mackay, Ph.D. and Paula Soteropoulos as Class I directors for a three-year term.
• The meeting will also include a vote to ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of Deloitte & Touche LLP.
• The record date for determining stockholders eligible to vote at the Annual Meeting was March 17, 2025.
• As of March 17, 2025, there were 41,612,039 shares of common stock outstanding and entitled to vote.
• The proxy statement and annual report are available online at www.proxyvote.com and www.rallybio.com.
• Stockholders can vote online, by telephone, by mail, or during the virtual meeting.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the board's recommendations and standard corporate governance practices. The company is following standard procedures for a public company.

Positives

• The virtual meeting format enables greater stockholder participation.
• Stockholders have multiple options for voting: online, telephone, mail, or during the virtual meeting.
• The Board of Directors is actively engaged in risk oversight through various committees and regular reports.
• The company has a Code of Business Conduct and Ethics for directors, officers, and employees.
• The company maintains a clawback policy for recouping erroneously-awarded incentive compensation.
• The company has adopted an insider trading policy in connection with the company's initial public offering in August 2021.

Negatives

• The document does not explicitly state any negative aspects of the company's performance or outlook.
• The company's stock price was $0.96 per share on December 31, 2024, which may be considered low.

Risks

• The document does not explicitly state any risks facing the company.
• The proxy statement mentions that the company is subject to risks related to its internal control over financial reporting, disclosure controls and procedures, and compliance matters.

Future Outlook

The document does not contain specific forward-looking statements about financial performance, but it outlines the company's plans for the annual meeting and ongoing corporate governance practices.

Management Comments

• Our Board of Directors recommends that you vote FOR each of the nominees for Class I director (Proposal 1) and FOR ratification of the proposed independent registered public accounting firm (Proposal 2).

Industry Context

This announcement is a standard part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions such as electing directors and ratifying the selection of the independent accounting firm.

Comparison to Industry Standards

• The structure of Rallybio's board and committees aligns with standard corporate governance practices for publicly traded companies in the United States.
• The company's compensation policies for executives and directors are benchmarked against a peer group of similar companies in the biotechnology industry.
• The virtual format of the annual meeting is becoming increasingly common, allowing for broader participation and reduced costs.
• The company's engagement of an independent compensation consultant (Pearl Meyer) is a best practice for ensuring fair and competitive compensation.

Related Party Transactions

• Dr. Mackay entered into a consulting agreement with the Company and Rallybio, LLC, effective January 1, 2025. The consulting agreement provides that Dr. Mackay will serve as a consultant to Rallybio from January 1, 2025 until January 1, 2026 and receive a consulting fee of $18,750 per month.

Stakeholder Impact

• Stockholders have the opportunity to vote on key decisions affecting the company's governance and direction.
• Employees are subject to the company's Code of Business Conduct and Ethics and insider trading policy.
• The selection of an independent accounting firm ensures the integrity of the company's financial reporting.
• The company's compensation policies aim to attract and retain qualified executives and directors.

Next Steps

• Stockholders will vote on the proposals outlined in the proxy statement.
• The Board of Directors will implement the decisions made at the Annual Meeting.
• The Audit Committee will continue to oversee the company's financial reporting and audit processes.
• The Compensation Committee will continue to review and adjust executive and director compensation policies.
• The Nominating and Corporate Governance Committee will continue to oversee corporate governance matters and board composition.

Key Dates

Keywords

Annual Meeting, Stockholders, Directors, Proxy Statement, Rallybio, Deloitte & Touche, Voting, Governance, Compensation, Audit Committee